This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Cleerly is dedicated to creating a new standard of care for heart disease by using FDA-cleared solutions powered by artificial intelligence. With this investment, we look forward to helping Cleerly expand its reach and impact, bringing this potentially life-saving innovation to more patients and health systems nationally.
“Biotronik 's focus on vascular interventional excellence is evident in our strategic investments and persistent dedication to innovation”, said Dr. Jörg Pochert, President of Vascular Intervention at Biotronik. For more information: www.biotronik.com References: 1 Kwong M.,
1 Atherosclerosis is a systemic disease that affects multiple vascular regions and is particularly severe in PAD patients, where up to 80 percent suffer from concurrent coronaryarterydisease (CAD), historically linked with a mortality rate exceeding 50 percent within five years. 301–302, [link]. 3 Secemsky, Eric A.,
The designation recognizes the novelty of the technology and the potential to provide a more effective treatment option for patients with coronaryarterydisease. The DynamX bioadaptor has a novel design and mechanism of action designed to return the diseased vessel to a more normal condition, through three distinct phases.
With more than 500 peer-reviewed publications, the HeartFlow FFR CT Analysis remains unparalleled in precision coronary care, as supported by the ACC/AHA Chest Pain Guidelines, to improve treatment plans and outcomes. 3 HeartFlow’s FFR CT Analysis is covered by Medicare and for >99% of commercially insured lives.
I think especially with the recent changes in guidelines and the recommendation to use CT for screening of coronaryarterydisease, we expect to see this trend really impact the way CT is used in the future.” “The CT procedural mix is evolving, and cardiac CT is starting to account for a large proportion of that.
The development has urged us to integrate the latest Artificial Intelligence with the healthcare system, including Cardiac Medicare. With the continued evolution of AI, it is now being introduced in cardiac healthcare, promising opportunities for innovation and advancements in cardiovascular medicine. What is Artificial Intelligence?
We organize all of the trending information in your field so you don't have to. Join thousands of users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content